Gateway Investment Advisers LLC Lowers Stock Holdings in Bristol Myers Squibb Company $BMY

Gateway Investment Advisers LLC trimmed its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 69.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 34,288 shares of the biopharmaceutical company’s stock after selling 79,169 shares during the period. Gateway Investment Advisers LLC’s holdings in Bristol Myers Squibb were worth $1,849,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Physician Wealth Advisors Inc. lifted its holdings in shares of Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 202 shares during the last quarter. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the second quarter valued at approximately $25,000. EQ Wealth Advisors LLC purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $32,000. Garner Asset Management Corp purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $35,000. Finally, Beacon Financial Strategies CORP purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $38,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.05% of the stock is currently owned by insiders.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $56.10 on Friday. The firm has a market cap of $114.56 billion, a PE ratio of 15.76, a P/E/G ratio of 0.16 and a beta of 0.26. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The firm has a fifty day simple moving average of $59.28 and a two-hundred day simple moving average of $54.91. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same period in the previous year, the business earned $1.80 EPS. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts anticipate that Bristol Myers Squibb Company will post 6.29 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.5%. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Analyst Ratings Changes

Several research firms have recently issued reports on BMY. Barclays began coverage on shares of Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price for the company. Piper Sandler restated an “overweight” rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. HSBC boosted their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Scotiabank restated a “sector perform” rating and issued a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Finally, UBS Group restated a “buy” rating and issued a $70.00 price objective on shares of Bristol Myers Squibb in a report on Friday, March 6th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.